IP Library Granted Patent US 7,125,899
Granted Patent B2
US 7,125,899 · App. 10/405,886 · Granted Oct 24, 2006

Epothilone derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,125,899
App. No.
10/405,886
Granted
Oct 24, 2006
Kind
B2
Abstract

The present invention relates to epothilone derivatives, having the following formula: in which the variables G, W, Q, X, Y, B 1 , B 2 , Z 1 , Z 2 , and R 1–R 7 are defined herein, methods for preparation of the derivatives and intermediates thereof.

Claims (31)

1. A compound having the formula V:

wherein,

Q is

R 8 is methyl;

G is 1-methyl-2-(2-methyl-4-thiazolyl)ethenyl;

W is NH;

X is O;

Y is O;

Z 1 and Z 2 are CH 2 ;

B 1 and B 2 are OH;

R 1 , R 2 , and R 7 are hydrogen; and

R 3 , R 4 , R 5 and R 6 are methyl; and/or a pharmaceutically-acceptable hydrate, solvate, and/or geometric, optical, and/or stereoisomer thereof.

2. A method of treating cancer in a patient comprising administering to the patient a therapeutically-effective amount of the compound according to claim 1 , and/or one or more hydrates, solvates, and/or isomers thereof, wherein the cancer is selected from one or more of cancer of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid, and/or prostate.

3. A method of treating breast cancer in a patient comprising administering to the patient a therapeutically-effective amount of the compound according to claim 1 , and/or one or more hydrates, solvates, and/or isomers thereof.

4. A method of treating lung cancer in a patient comprising administering to the patient a therapeutically-effective amount of the compound according to claim 1 , and/or one or more hydrates, solvates, and/or isomers thereof.

5. A pharmaceutical composition comprising the compound according to claim 1 , and/or one or more hydrates, solvates, and/or isomers thereof, and one or more pharmaceutically-acceptable diluents, vehicles and/or additives.

6. A method of treating cancer in a patient comprising administering to the patient a therapeutically-effective amount of the pharmaceutical composition according to claim 5 , wherein the cancer is selected from one or more of cancer of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid, and/or prostate.

7. A compound having the formula:

8. A solvate of the compound of claim 7 .

9. A hydrate of the compound of claim 7 .

10. A compound which is a geometric, optical or stereoisomer of the compound of claim 7 , or a mixture comprising the compound of claim 7 and one or more geometric, optical and/or stereoisomers of the compound of claim 7 .

11. A pharmaceutical composition comprising a solvate according to claim 8 and a pharmaceutically-acceptable diluent, vehicle, and/or additive.

12. A pharmaceutical composition comprising a hydrate according to claim 9 and a pharmaceutically-acceptable diluent, vehicle, and/or additive.

13. A pharmaceutical composition comprising a compound or mixture of compounds according to claim 10 and a pharmaceutically-acceptable diluent, vehicle, and/or additive.

14. A method of treating cancer in a patient comprising administering to the patient a therapeutically-effective amount of a pharmaceutical composition according to claim 11 , wherein the cancer is selected from one or more of cancer of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid, and/or prostate.

15. A method of treating cancer in a patient comprising administering to the patient a therapeutically-effective amount of a pharmaceutical composition according to claim 12 , wherein the cancer is selected from one or more of cancer of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid, and/or prostate.

16. A method of treating cancer in a patient comprising administering to the patient a therapeutically-effective amount of a pharmaceutical composition according to claim 13 , wherein the cancer is selected from one or more of cancer of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid, and/or prostate.

17. The method of claim 16 comprising the treatment of breast cancer.

18. The method of claim 2 comprising the treatment of prostate cancer.

19. The method of claim 2 comprising the treatment of kidney cancer.

20. The method of claim 2 comprising the treatment of pancreatic cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2015
From: BRISTOL-MYERS SQUIBB COMPANY
To: R-PHARM US OPERATING LLC
Reel/Frame 036585/0956 →